Text size :

Drugs, Cognetti (Foce): “Therapies and tests follow independent paths, the gap must be bridged”

ADNKRONOS

November 12, 2026

Rome, Nov 12. (Adnkronos Health) – “The two processes are absolutely independent. The approval and reimbursement process for drugs is already long: from the company’s submission of the application to publication in the Official Gazette and subsequent regional steps, about two years can pass.” This was stated by Francesco Cognetti, president of Foce – Confederation of oncologists, cardiologists and hematologists, during the event “Essential levels of assistance and Next Generation Sequencing, The challenge of innovation between updating and access”, organized in Rome by Salutequità.

“When, then, the drug is directed against specific molecular targets, a test is necessary to identify patients who can benefit from it; however, the approval and reimbursement of tests are not linked to those of the drug and may arrive later, through the updating of the LEA. The result is a further delay in access to care,” explained Cognetti.

Even the updating of essential levels “remains insufficient compared to the current reality: it is necessary to intervene promptly, update tests in relation to drugs and make the new LEA effective in all Regions. It is not enough – he concluded – for a Region to achieve partial coverage of essential levels: these are services that must be guaranteed.”

Jiji Press

Related

Page TOP